Bibliography: library/10665-352523

The reference for library/10665-352523 (who-iris) and any references extracted from it. library · All references.

Export these 231 references: BibTeX · CSL-JSON · RIS · Dublin Core XML · Dublin Core / BIBO JSON-LD

✍ + Add reference (standalone node)

Build a standalone folio-reference/v1 node at references/reference.jsonld from fields or pasted BibTeX / CSL-JSON.



· ✍ Create standalone node on GitHub · Download .jsonld · Download .csl.json ·

231 shown

  1. World Health Organization (2022). WHO operational handbook on tuberculosis: module 5: management of tuberculosis in children and adolescents. World Health Organization.
    10665-352523 · catalogue · link · repository record · ISBN 9789240046832 (electronic version) · source: catalogue/records/10665-352523.dc.json · held: library/10665-352523
    export: BibTeX · RIS · CSL-JSON · DC XML
  2. Global tuberculosis report 2021. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/346387, accessed 1 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.1.json
  3. Snow KJ, Sismanidis C, Denholm J, et al. The incidence of tuberculosis among adolescents and young adults: a global estimate. Eur Respir J. 2018;51(2):1702352.
    · extracted · source: references/10665-352523.sec-045.2.json
  4. WHO consolidated guidelines on tuberculosis. Module 5: management of tuberculosis in children and adolescents. Geneva: World Health Organization; 2022 (https://apps.who.int/iris/bitstream/handle/10665/352522/9789240046764-eng.pdf).
    · extracted · link · source: references/10665-352523.sec-045.3.json · held: library/10665-352522
  5. Marais B. The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. Int J Tuberc Lung Dis. 2004;8(4):392–402.
    · extracted · source: references/10665-352523.sec-045.4.json
  6. Roadmap towards ending TB in children and adolescents. Geneva: World Health Organization; 2018 (https://apps.who.int/iris/handle/10665/275422, accessed 1 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.5.json
  7. Guidance for national tuberculosis programmes on the management of tuberculosis in children, second edition. Geneva: World Health Organization; 2014 (https://apps.who.int/iris/handle/10665/112360, accessed 1 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.6.json
  8. The End TB Strategy: global strategy and targets for tuberculosis prevention, care and control after 2015. Geneva: World Health Organization; 2014 (https://apps.who.int/iris/handle/10665/162760, accessed 1 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.7.json
  9. The Sustainable Development Agenda. New York: United Nations (https://www.un.org/sustainabledevelopment/development-agenda/, accessed 1 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.8.json
  10. Political declaration of the UN General-Assembly High-level meeting on the fight against tuberculosis. New York: United Nations; 2018 (https://www.who.int/docs/default-source/documents/tuberculosis/political-declaration-un-general-assembly-tb-tuberculosis.pdf?sfvrsn=4f4090dc_1&download=true, accessed 1 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.9.json
  11. Houben R, Lalli M, Kranzer K, et al. What if they don’t have tuberculosis? The consequences and trade-offs involved in false-positive diagnoses of tuberculosis. Clin Infect Dis. 2019;68(1):150–156.
    · extracted · source: references/10665-352523.sec-045.10.json
  12. Dodd PJ, Gardiner E, Coghlan R, Seddon JA. Burden of childhood tuberculosis in 22 high-burden countries: a mathematical modelling study. Lancet Glob Health. 2014;2(8):e453–e459.
    · extracted · source: references/10665-352523.sec-045.11.json
  13. Dodd PJ, Sismanidis C, Seddon JA. Global burden of drug-resistant tuberculosis in children: a mathematical modelling study. Lancet Infect Dis. 2016;16(10):1193–1201.
    · extracted · source: references/10665-352523.sec-045.12.json
  14. WHO operational handbook on tuberculosis. Module 2: screening – systematic screening for tuberculosis disease. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/340256, accessed 1 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.13.json
  15. WHO consolidated guidelines on tuberculosis. Module 2: screening – systematic screening for tuberculosis disease. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/340255, accessed 1 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.14.json · held: library/10665-340255
  16. WHO operational handbook on tuberculosis. Module 1: prevention – tuberculosis preventive treatment. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/handle/10665/331525, accessed 1 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.15.json · held: library/10665-331525
  17. Martinez L, Cords O, Horsburgh CR, et al. The risk of tuberculosis in children after close exposure: a systematic review and individual-participant meta-analysis. Lancet. 2020;395(10228):973–984.
    · extracted · source: references/10665-352523.sec-045.16.json
  18. Dodd PJ, Yuen CM, Sismanidis C, et al. The global burden of tuberculosis mortality in children: a mathematical modelling study. Lancet Glob Health. 2017;5(9):e898-e906.
    · extracted · source: references/10665-352523.sec-045.17.json
  19. Gupta A, Swindells S, Kim S, et al. Feasibility of identifying household contacts of rifampin- and multidrug-resistant tuberculosis cases at high risk of progression to tuberculosis disease. Clin Infect Dis. 2020;70(3):425–435.
    · extracted · source: references/10665-352523.sec-045.18.json
  20. Lung T, Marks GB, Nhung NV, et al. Household contact investigation for the detection of tuberculosis in Vietnam: economic evaluation of a cluster-randomised trial. Lancet Glob Health. 2019;7(3):e376–e384.
    · extracted · source: references/10665-352523.sec-045.19.json
  21. Sulis G, Combary A, Getahun H, et al. Implementation of tuberculosis prevention for exposed children, Burkina Faso. Bull World Health Org. 2018;96(6):386–392.
    · extracted · source: references/10665-352523.sec-045.20.json
  22. Kay AW, Sandoval M, Mtetwa G, et al. Vikela Ekhaya: a novel, community-based, tuberculosis contact management program in a high burden setting. Clin Infect Dis. 2021; (https://doi.org/10.1093/cid/ciab652, accessed 1 December 2021).
    · extracted · doi:10.1093/cid/ciab652 · source: references/10665-352523.sec-045.21.json
  23. Recommendations for investigating contacts of persons with infectious tuberculosis in low- and middle-income countries. Geneva: World Health Organization; 2012 (https://apps.who.int/iris/handle/10665/77741, accessed 1 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.22.json
  24. Padyana M, Bhat RV, Dinesha M, Nawaz A. HIV-tuberculosis: a study of chest X-ray patterns in relation to CD4 count. N Am J Med Sci. 2012;4(5):221–225.
    · extracted · source: references/10665-352523.sec-045.23.json
  25. Colditz GA, Berkey CS, Mosteller F, et al. The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics. 1995;96(1 Pt 1):29–35.
    · extracted · source: references/10665-352523.sec-045.24.json
  26. Vonasek B, Ness T, Takwoingi Y, et al. Screening tests for active pulmonary tuberculosis in children. Cochrane Database Syst Rev. 2021;6(6):CD013693.
    · extracted · source: references/10665-352523.sec-045.25.json
  27. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis – rapid diagnostics for tuberculosis detection, 2021 update. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/342331, accessed 1 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.26.json
  28. Use of tuberculosis interferon-gamma release assays (IGRAs) in low- and middle-income countries: policy statement. Geneva: World Health Organization; 2011 (https://apps.who.int/iris/handle/10665/44759, accessed 1 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.27.json · held: library/10665-44759
  29. WHO consolidated guidelines on tuberculosis. Module 1: prevention – tuberculosis preventive treatment. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/handle/10665/331170, accessed 1 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.28.json · held: library/10665-331170
  30. Colditz GA, Brewer TF, Berkey CS, et al. Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature. JAMA. 1994;271(9):698–702.
    · extracted · source: references/10665-352523.sec-045.29.json
  31. Blok L, Sahu S, Creswell J, et al. Comparative meta-analysis of tuberculosis contact investigation interventions in eleven high burden countries. PLoS One. 2015;10(3):e0119822.
    · extracted · source: references/10665-352523.sec-045.30.json
  32. BCG vaccines: WHO position paper – February 2018. Geneva: World Health Organization: 2018 (https://apps.who.int/iris/handle/10665/260307, accessed 1 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.31.json
  33. Prentice S, Nassanga B, Webb EL, et al. BCG-induced non-specific effects on heterologous infectious disease in Ugandan neonates: an investigator-blind randomised controlled trial. Lancet Infect Dis. 2021;21(7):993–1003.
    · extracted · source: references/10665-352523.sec-045.32.json
  34. Information sheet: observed rate of vaccine reactions – bacille Calmette-Guérin (BCG) vaccine. Geneva: World Health Organization; 2012.
    · extracted · source: references/10665-352523.sec-045.33.json
  35. Hesseling AC, Johnson LF, Jaspan H, et al. Disseminated bacille Calmette-Guerin disease in HIV-infected South African infants. Bull World Health Organ. 2009;87(7):505–511.
    · extracted · source: references/10665-352523.sec-045.34.json
  36. Cuello-Garcia CA, Perez-Gaxiola G, Jimenez Gutierrez C. Treating BCG-induced disease in children. Cochrane Database Syst Rev. 2013;(1):CD008300.
    · extracted · source: references/10665-352523.sec-045.35.json
  37. Hesseling AC, Rabie H, Marais BJ, et al. Bacille Calmette-Guérin vaccine-induced disease in HIV-infected and HIV-uninfected children. Clin Infect Dis. 2006;42(4):548–558.
    · extracted · source: references/10665-352523.sec-045.36.json
  38. Venkataraman A, Yusuff M, Liebeschuetz S, et al. Management and outcome of Bacille Calmette-Guerin vaccine adverse reactions. Vaccine. 2015;33(41):5470–5474.
    · extracted · source: references/10665-352523.sec-045.37.json
  39. Curtis N, Sparrow A, Ghebreyesus TA, Netea MG. Considering BCG vaccination to reduce the impact of COVID-19. Lancet. 2020;395(10236):1545–1546.
    · extracted · source: references/10665-352523.sec-045.38.json
  40. Fritschi N, Curtis N, Ritz N. Bacille Calmette Guerin (BCG) and new TB vaccines: specific, cross-mycobacterial and off-target effects. Paediatr Respir Rev. 2020;36:57–64.
    · extracted · source: references/10665-352523.sec-045.39.json
  41. Marais BJ, Seddon JA, Detjen AK, et al. Interrupted BCG vaccination is a major threat to global child health. Lancet Respir Med. 2016;4(4):251–253.
    · extracted · source: references/10665-352523.sec-045.40.json
  42. Kontturi A, Santiago B, Tebruegge M, et al. The impact of Bacille Calmette-Guérin shortage on immunisation practice and policies in Europe: a Paediatric Tuberculosis Network European Trials Group (ptbnet) survey. Tuberculosis (Edinb). 2016;101:125–129.
    · extracted · source: references/10665-352523.sec-045.41.json
  43. Du Preez K, Seddon JA, Schaaf HS, et al. Global shortages of BCG vaccine and tuberculous meningitis in children. Lancet Glob Health. 2019;7(1):e28–e29.
    · extracted · source: references/10665-352523.sec-045.42.json
  44. Cernuschi T, Malvolti S, Nickels E, Friede M. Bacillus Calmette-Guerin (BCG) vaccine: a global assessment of demand and supply balance. Vaccine. 2018;36(4):498–506.
    · extracted · source: references/10665-352523.sec-045.43.json
  45. Global market study: BCG vaccine. Geneva: World Health Organization; 2019 (https://www.who.int/immunization/programmes_systems/procurement/v3p/platform/module2/WHO_BCG_vaccine_global_market_update_Feb2019.pdf, accessed 1 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.44.json
  46. Bacille Calmette-Guérin (BCG) vaccination and COVID-19: scientific brief – 12 April 2020. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/handle/10665/331745, accessed 1 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.45.json
  47. Dodd PJ, Prendergast AJ, Beecroft C, et al. The impact of HIV and antiretroviral therapy on TB risk in children: a systematic review and meta-analysis. Thorax. 2017;72(6):559–575.
    · extracted · source: references/10665-352523.sec-045.46.json
  48. Ford N, Matteelli A, Shubber Z, et al. TB as a cause of hospitalization and in-hospital mortality among people living with HIV worldwide: a systematic review and meta-analysis. J Int AIDS Soc. 2016;19(1):20714.
    · extracted · source: references/10665-352523.sec-045.47.json
  49. Badje A, Moh R, Gabillard D, et al. Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial. Lancet Glob Health. 2017;5(11):e1080–e1089.
    · extracted · source: references/10665-352523.sec-045.48.json
  50. Guidelines for intensified tuberculosis case-finding and isoniazid preventative therapy for people living with HIV in resource-constrained settings. Geneva: World Health Organization; 2011 (https://apps.who.int/iris/handle/10665/44472, accessed 1 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.49.json
  51. Bruins WS, van Leth F. Effect of secondary preventive therapy on recurrence of tuberculosis in HIV-infected individuals: a systematic review. Infect Dis (Lond). 2017;49(3):161–169.
    · extracted · source: references/10665-352523.sec-045.50.json
  52. Cotton MF, Schaaf HS, Lottering G, et al. Tuberculosis exposure in HIV-exposed infants in a high-prevalence setting. Int J Tuberc Lung Dis. 2008;12(2):225–227.
    · extracted · source: references/10665-352523.sec-045.51.json
  53. Cranmer LM, Kanyugo M, Jonnalagadda SR, et al. High prevalence of tuberculosis infection in HIV-1 exposed Kenyan infants. Pediatr Infect Dis J. 2014;33(4):401–406.
    · extracted · source: references/10665-352523.sec-045.52.json
  54. Kali PB, Gray GE, Violari A, et al. Combining PMTCT with active case finding for tuberculosis. J Acquir Immune Defic Syndr. 2006;42(3):379–381.
    · extracted · source: references/10665-352523.sec-045.53.json
  55. Sterling TR, Alwood K, Gachuhi R, et al. Relapse rates after short-course (6-month) treatment of tuberculosis in HIV-infected and uninfected persons. Aids. 1999;13(14):1899–1904.
    · extracted · source: references/10665-352523.sec-045.54.json
  56. Vernon A, Burman W, Benator D, et al. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet. 1999;353(9167):1843–1847.
    · extracted · source: references/10665-352523.sec-045.55.json
  57. Small PM, Shafer RW, Hopewell PC, et al. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med. 1993;328(16):1137–1144.
    · extracted · source: references/10665-352523.sec-045.56.json
  58. Crampin AC, Mwaungulu JN, Mwaungulu FD, et al. Recurrent TB: relapse or reinfection? The effect of HIV in a general population cohort in Malawi. AIDS. 2010;24(3):417–426.
    · extracted · source: references/10665-352523.sec-045.57.json
  59. Narayanan S, Swaminathan S, Supply P, et al. Impact of HIV infection on the recurrence of tuberculosis in South India. J Infect Dis. 2010;201(5):691–703.
    · extracted · source: references/10665-352523.sec-045.58.json
  60. Chaisson RE, Churchyard GJ. Recurrent tuberculosis: relapse, reinfection, and HIV. J Infect Dis. 2010;201(5):653–655.
    · extracted · source: references/10665-352523.sec-045.59.json
  61. Naidoo K, Dookie N. Insights into recurrent tuberculosis: relapse versus reinfection and related risk factors. In Kayembe J-M, editor. Tuberculosis. London: IntechOpen; 2018 (https://www.intechopen.com/books/tuberculosis/insights-into-recurrenttuberculosis-relapse-versus-reinfection-and-related-risk-factors, accessed 1 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.60.json
  62. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: World Health Organization; 2018 (https://apps.who.int/iris/handle/10665/260233, accessed 8 March 2022).
    · extracted · link · source: references/10665-352523.sec-045.61.json
  63. TB elimination: interferon-gamma release assays (IGRAs) – blood tests for TB infection. Atlanta, GA: Centers for Disease Control and Prevention (https://www.cdc.gov/tb/publications/factsheets/testing/IGRA.pdf, accessed 1 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.62.json
  64. Getahun H, Matteelli A, Chaisson RE, Raviglione M. Latent Mycobacterium tuberculosis infection. N Engl J Med. 2015;372(22):2127–2135.
    · extracted · source: references/10665-352523.sec-045.63.json
  65. Salgame P, Geadas C, Collins L, et al. Latent tuberculosis infection: revisiting and revising concepts. Tuberculosis (Edinb). 2015;95(4):373–384.
    · extracted · source: references/10665-352523.sec-045.64.json
  66. Schwoebel V, Koura KG, Adjobimey M, et al. Tuberculosis contact investigation and short-course preventive therapy among young children in Africa. Int J Tuberc Lung Dis. 2020;24(4):452–460.
    · extracted · source: references/10665-352523.sec-045.65.json
  67. Report of the meeting to review the paediatric antituberculosis drug optimization priority list. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/340316, accessed 1 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.66.json
  68. Becerra MC, Huang C-C, Lecca L, et al. Transmissibility and potential for disease progression of drug resistant Mycobacterium tuberculosis: prospective cohort study. BMJ. 2019;367:l5894.
    · extracted · source: references/10665-352523.sec-045.67.json
  69. Marks SM, Mase SR, Morris SB. Systematic review, meta-analysis, and cost-effectiveness of treatment of latent tuberculosis to reduce progression to multidrug-resistant tuberculosis. Clin Infect Dis. 2017;64(12):1670–1677.
    · extracted · source: references/10665-352523.sec-045.68.json
  70. Handbook for the use of digital technologies to support tuberculosis medication adherence. Geneva: World Health Organization; 2017 (https://apps.who.int/iris/handle/10665/259832, accessed 1 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.69.json
  71. WHO guidelines on tuberculosis infection prevention and control, 2019 update. Geneva: World Health Organization; 2019 (https://apps.who.int/iris/handle/10665/311259, accessed 1 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.70.json
  72. Definitions and reporting framework for tuberculosis: 2013 revision (updated December 2014 and January 2020). Geneva: World Health Organization; 2013 (https://apps.who.int/iris/handle/10665/79199, accessed 3 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.71.json
  73. The Union’s desk guide for diagnosis and management of TB in children, third edition. Paris: International Union Against Tuberculosis and Lung Disease; 2016 (https://theunion.org/sites/default/files/2020–08/2016_Desk-guide_Africa_Web.pdf, accessed 3 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.72.json
  74. Kay AW, Gonzalez Fernandez L, Takwoingi Y, et al. Xpert MTB/RIF and Xpert MTB/RIF Ultra assays for active tuberculosis and rifampicin resistance in children. Cochrane Database Syst Rev. 2020;8:CD013359.
    · extracted · source: references/10665-352523.sec-045.73.json
  75. Jasumback CL, Dlamini Q, Kahari J, et al. Laboratory comparison of stool processing methods for Xpert ® Ultra. Public Health Action. 2021;11(2):55–57.
    · extracted · source: references/10665-352523.sec-045.74.json
  76. Zar HJ, Workman L, Isaacs W, et al. Rapid molecular diagnosis of pulmonary tuberculosis in children using nasopharyngeal specimens. Clin Infect Dis. 2012;55(8):1088–1095.
    · extracted · source: references/10665-352523.sec-045.75.json
  77. World Health Organization. WHO operational handbook on tuberculosis. Module 3: diagnosis – rapid diagnostics for tuberculosis detention, 2021 update. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/342369, accessed 1 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.76.json
  78. Package of care for children and adolescents with advanced HIV disease: stop AIDS. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/handle/10665/332907, accessed 6 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.77.json · held: library/10665-332907
  79. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/342899, accessed 1 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.78.json
  80. Fry SH, Barnabas SL, Cotton MF. Tuberculosis and HIV: an update on the “cursed duet” in children. Front Pediatr. 2019;7:159.
    · extracted · source: references/10665-352523.sec-045.79.json
  81. Integrated Management of Childhood Illness: chart booklet. Geneva: World Health Organization; 2014 (https://apps.who.int/iris/handle/10665/104772, accessed 1 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.80.json
  82. Updated guideline: paediatric emergency triage, assessment and treatment – care of critically ill children. Geneva: World Health Organization; 2016 (https://apps.who.int/iris/handle/10665/204463, accessed 8 March 2022).
    · extracted · link · source: references/10665-352523.sec-045.81.json
  83. WHO operational handbook on tuberculosis. Module 4: treatment – drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/handle/10665/332398, accessed 2 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.82.json
  84. Chiang SS, Brooks MB, Jenkins HE, et al. Concordance of drug-resistance profiles between persons with drug-resistant tuberculosis and their household contacts: a systematic review and meta-analysis. Clin Infect Dis. 2021;73(2):250–263.
    · extracted · source: references/10665-352523.sec-045.83.json
  85. Management of drug-resistant tuberculosis in children: a field guide. Boston, MA: Sentinel Project for Pediatric Drug-Resistant Tuberculosis; 2019 (http://sentinel-project.org/wp-content/uploads/2019/02/Updated_DRTB-Field-Guide-2019-V3.pdf, accessed 2 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.84.json
  86. Jenkins HE, Yuen CM, Rodriguez CA, et al. Mortality in children diagnosed with tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2017;17(3):285–295.
    · extracted · source: references/10665-352523.sec-045.85.json
  87. Turkova A, Wills GA, Wobudeya E, et al. Shorter treatment for nonsevere tuberculosis in African and Indian children. N Engl J Med. 2022;386(7).
    · extracted · source: references/10665-352523.sec-045.86.json
  88. WHO consolidated guidelines on tuberculosis. Module 4: treatment – drug-susceptible tuberculosis treatment. Geneva: World Health Organization; 2022 (https://www.who.int/publications/i/item/9789240048126, accessed 8 March 2022).
    · extracted · link · source: references/10665-352523.sec-045.87.json
  89. Graham SM, Grzemska M, Gie RP. The background and rationale for a new fixed-dose combination for first-line treatment of tuberculosis in children. Int J Tuberc Lung Dis. 2015;19(Suppl 1):3–8.
    · extracted · source: references/10665-352523.sec-045.88.json
  90. Donald PR, Maher D, Maritz JS, Qazi S. Ethambutol dosage for the treatment of children: literature review and recommendations. Int J Tuberc Lung Dis. 2006;10(12):1318–1330.
    · extracted · source: references/10665-352523.sec-045.89.json
  91. WHO case definitions of HIV for surveillance and revised clinical staging and immunological classification of HIV-related disease in adults and children. Geneva: World Health Organization; 2007 (https://apps.who.int/iris/handle/10665/43699, accessed 6 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.90.json · held: library/10665-43699
  92. Guideline: updates on the management of severe acute malnutrition in infants and children. Geneva: World Health Organization; 2013 (https://apps.who.int/iris/handle/10665/95584, accessed 8 March 2022).
    · extracted · link · source: references/10665-352523.sec-045.91.json
  93. Schaaf HS, Marais BJ, Whitelaw A, et al. Culture-confirmed childhood tuberculosis in Cape Town, South Africa: a review of 596 cases. BMC Infect Dis. 2007;7(1):140.
    · extracted · source: references/10665-352523.sec-045.92.json
  94. Wolzak NK, Cooke ML, Orth H, van Toorn R. The changing profile of pediatric meningitis at a referral centre in Cape Town, South Africa. J Trop Pediatr. 2012;58(6):491–495.
    · extracted · source: references/10665-352523.sec-045.93.json
  95. Chiang SS, Khan FA, Milstein MB, et al. Treatment outcomes of childhood tuberculous meningitis: a systematic review and meta-analysis. Lancet Infect Dis. 2014;14(10):947–957.
    · extracted · source: references/10665-352523.sec-045.94.json
  96. Van Toorn R, Schaaf HS, Laubscher JA, et al. Short intensified treatment in children with drug-susceptible tuberculous meningitis. Pediatr Infect Dis J. 2014;33(3):248–252.
    · extracted · source: references/10665-352523.sec-045.95.json
  97. Van Well GT, Paes BF, Terwee CB, et al. Twenty years of pediatric tuberculous meningitis: a retrospective cohort study in the western cape of South Africa. Pediatrics. 2009;123(1):e1–e8.
    · extracted · source: references/10665-352523.sec-045.96.json
  98. Rapid advice: treatment of tuberculosis in children. Geneva: World Health Organization; 2010 (https://apps.who.int/iris/handle/10665/44444, accessed 8 March 2022).
    · extracted · link · source: references/10665-352523.sec-045.97.json
  99. Donald PR. The chemotherapy of tuberculous meningitis in children and adults. Tuberculosis (Edinb). 2010;90(6):375–392.
    · extracted · source: references/10665-352523.sec-045.98.json
  100. Guidelines for the management of tuberculosis in children. Pretoria: Department of Health; 2013 (www.kznhealth.gov.za/family/National-Childhood-TB-Guidelines-2013-ZA.pdf, accessed 11 March 2022).
    · extracted · link · source: references/10665-352523.sec-045.99.json
  101. Statement on the use of child-friendly fixed-dose combinations for the treatment of TB in children. Geneva; World Health Organization and United Nations Children’s Fund; 2017 (https://cdn.who.int/media/docs/default-source/documents/tuberculosis/statement-on-the-use-of-child-friendly-fixed-dose-combinations-for-the-treatment-of-tb-in-children8ce21e28-f351–4abe-92de-4b757cf2d0d8.pdf?sfvrsn=82f15c83_1&download=true, accessed 11 March 2022).
    · extracted · link · source: references/10665-352523.sec-045.100.json
  102. New pathways for childhood TB treatment: lessons from the STEP-TB Project. New York and Vernier: TB Alliance and Unitaid; 2017 (https://www.tballiance.org/sites/default/files/child-resources/New_Pathways_for_Childhood_TB_Treatment.pdf, accessed 6 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.101.json
  103. Prasad K, Singh MB, Ryan H. Corticosteroids for managing tuberculous meningitis. Cochrane Database Syst Rev. 2016;4(4):CD002244.
    · extracted · source: references/10665-352523.sec-045.102.json
  104. Schoeman JF, Van Zyl LE, Laubscher JA, Donald PR. Effect of corticosteroids on intracranial pressure, computed tomographic findings, and clinical outcome in young children with tuberculous meningitis. Pediatrics. 1997;99(2):226–231.
    · extracted · source: references/10665-352523.sec-045.103.json
  105. Essential nutrition actions: mainstreaming nutrition through the life-course. Geneva: World Health Organization; 2019 (https://apps.who.int/iris/handle/10665/326261, accessed 8 March 2022).
    · extracted · link · source: references/10665-352523.sec-045.104.json
  106. Guideline: nutritional care and support for patients with tuberculosis. Geneva: World Health Organization; 2013 (https://apps.who.int/iris/handle/10665/94836, accessed 6 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.105.json
  107. Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med. 2006;174(8):935–952.
    · extracted · source: references/10665-352523.sec-045.106.json
  108. Guidelines for treatment of drug-susceptible tuberculosis and patient care: 2017 update. Geneva: World Health Organization; 2017 (https://apps.who.int/iris/handle/10665/255052, accessed 8 March 2022).
    · extracted · link · source: references/10665-352523.sec-045.107.json
  109. Meeting report of the WHO expert consultation on drug-resistant tuberculosis treatment outcome definitions, 17–19 November 2020. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/340284, accessed 6 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.108.json
  110. Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63(7):e147–e195.
    · extracted · source: references/10665-352523.sec-045.109.json
  111. Jenkins HE, Tolman AW, Yuen CM, et al. Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates. Lancet. 2014;383(9928):1572–1579.
    · extracted · source: references/10665-352523.sec-045.110.json
  112. Harausz EP, Garcia-Prats AJ, Law S, et al. Treatment and outcomes in children with multidrug-resistant tuberculosis: a systematic review and individual patient data meta-analysis. PLoS Med. 2018;15(7):e1002591.
    · extracted · source: references/10665-352523.sec-045.111.json
  113. Seddon JA, Hesseling AC, Godfrey-Faussett P, Schaaf HS. High treatment success in children treated for multidrug-resistant tuberculosis: an observational cohort study. Thorax. 2014;69(5):458–464.
    · extracted · source: references/10665-352523.sec-045.112.json
  114. Shah NS, Yuen CM, Heo M, et al. Yield of contact investigations in households of patients with drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis. 2014;58(3):381–391.
    · extracted · source: references/10665-352523.sec-045.113.json
  115. Ettehad D, Schaaf HS, Seddon JA, et al. Treatment outcomes for children with multidrug-resistant tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(6):449–456.
    · extracted · source: references/10665-352523.sec-045.114.json
  116. Gegia M, Jenkins HE, Kalandadze I, Furin J. Outcomes of children treated for tuberculosis with second-line medications in Georgia, 2009–2011. Int J Tuberc Lung Dis. 2013;17(5):624–629.
    · extracted · source: references/10665-352523.sec-045.115.json
  117. WHO consolidated guidelines on tuberculosis. Module 4: treatment – drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/handle/10665/332397, accessed 2 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.116.json
  118. Dooley KE, Rosenkranz SL, Conradie F, et al. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial. Lancet Infect Dis. 2021;21(7):975–983.
    · extracted · source: references/10665-352523.sec-045.117.json
  119. Svensson EM, Aweeka F, Park JG, et al. Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis. Antimicrob Agents Chemother. 2013;57(6):2780–2787.
    · extracted · source: references/10665-352523.sec-045.118.json
  120. Svensson EM, Dooley KE, Karlsson MO. Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection. Antimicrob Agents Chemother. 2014;58(11):6406–6412.
    · extracted · source: references/10665-352523.sec-045.119.json
  121. Brill MJ, Svensson EM, Pandie M, et al. Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug-resistant tuberculosis. Int J Antimicrob Agents. 2017;49(2):212–217.
    · extracted · source: references/10665-352523.sec-045.120.json
  122. Mallikaarjun S, Wells C, Petersen C, et al. Delamanid coadministered with antiretroviral drugs or antituberculosis drugs shows no clinically relevant drug–drug interactions in healthy subjects. Antimicrob Agents Chemother. 2016;60(10):5976–5985.
    · extracted · source: references/10665-352523.sec-045.121.json
  123. StopTB Partnership Global Drug Facility Paediatric Drug-Resistant TB (DR-TB) Donation Initiative [website]. Boston: Sentinel Project on Pediatric Drug-Resistant Tuberculosis; 2019 (http://sentinel-project.org/2019/02/18/stoptbgdfs-paediatric-drug-resistant-tb-dr-tb-donation-initiative/, accessed 16 March 2022).
    · extracted · link · source: references/10665-352523.sec-045.122.json
  124. Svensson EM, du Bois J, Kitshoff R, et al. Relative bioavailability of bedaquiline tablets suspended in water: implications for dosing in children. Br J Clin Pharmacol. 2018;84(10):2384–2392.
    · extracted · source: references/10665-352523.sec-045.123.json
  125. Schaaf HS, Thee S, van der Laan L, et al. Adverse effects of oral second-line antituberculosis drugs in children. Expert Opin Drug Saf. 2016;15(10):1369–1381.
    · extracted · source: references/10665-352523.sec-045.124.json
  126. Garcia-Prats AJ, Schaaf HS, Hesseling AC. The safety and tolerability of the second-line injectable antituberculosis drugs in children. Expert Opin Drug Saf. 2016;15(11):1491–1500.
    · extracted · source: references/10665-352523.sec-045.125.json
  127. Schaaf HS, Garcia-Prats AJ, McKenna L, Seddon JA. Challenges of using new and repurposed drugs for the treatment of multidrug-resistant tuberculosis in children. Expert Rev Clin Pharmacol. 2018;11(3):233–244.
    · extracted · source: references/10665-352523.sec-045.126.json
  128. Garcia-Prats AJ, Schaaf HS, Draper HR, et al. Pharmacokinetics, optimal dosing, and safety of linezolid in children with multidrug-resistant tuberculosis: combined data from two prospective observational studies. PLoS Med. 2019;16(4):e1002789.
    · extracted · source: references/10665-352523.sec-045.127.json
  129. Isaakidis P, Paryani R, Khan S, et al. Poor outcomes in a cohort of HIV-infected adolescents undergoing treatment for multidrug-resistant tuberculosis in Mumbai, India. PLoS One. 2013;8(7):e68869.
    · extracted · source: references/10665-352523.sec-045.128.json
  130. Moyo S, Furin JJ, Hughes J, et al. Outcomes in adolescents undergoing treatment for drug-resistant tuberculosis in Cape Town, South Africa, 2008–2013. Arch Pediatr Infect Dis. 2015;3(1 TB):e17934.
    · extracted · source: references/10665-352523.sec-045.129.json
  131. A family-centered approach to the treatment and prevention of drug-resistant tuberculosis in children and adolescents: Counselling tools and approach. Khayelitsha: Medecins Sans Frontieres; 2021 (http://sentinel-project.org/wp-content/uploads/2021/12/Peds_Counseling_Outline_V3.pdf, accessed 12 March 2022).
    · extracted · link · source: references/10665-352523.sec-045.130.json
  132. Allwood BW, Byrne A, Meghji J, et al. Post-tuberculosis lung disease: clinical review of an under-recognised global challenge. Respiration. 2021;100(8):751–763.
    · extracted · source: references/10665-352523.sec-045.131.json
  133. Allwood BW, Amaral AFS, Byrne A, et al. Post-tuberculosis lung health: perspectives from the First International Symposium. Int J Tuberc Lung Dis. 2020;24(8):820–828.
    · extracted · source: references/10665-352523.sec-045.132.json
  134. Dodd PJ, Yuen CM, Jayasooriya SM, et al. Quantifying the global number of tuberculosis survivors: a modelling study. Lancet Infect Dis. 2021;21(7):984–992.
    · extracted · source: references/10665-352523.sec-045.133.json
  135. Schoeman J, Wait J, Burger M, et al. Long-term follow up of childhood tuberculous meningitis. Dev Med Child Neurol. 2002;44(8):522–526.
    · extracted · source: references/10665-352523.sec-045.134.json
  136. Gupta R, Kushwaha S, Thakur R, et al. Predictors of adverse outcome in patients of tuberculous meningitis in a multi-centric study from India. Indian J Tuberc. 2017;64(4):296–301.
    · extracted · source: references/10665-352523.sec-045.135.json
  137. Dhawan SR, Gupta A, Singhi P, et al. Predictors of neurological outcome of tuberculous meningitis in childhood: a prospective cohort study from a developing country. J Child Neurol. 2016;31(14):1622–1627.
    · extracted · source: references/10665-352523.sec-045.136.json
  138. Davis AG, Nightingale S, Springer PE, et al. Neurocognitive and functional impairment in adult and paediatric tuberculous meningitis. Wellcome Open Res. 2019;4:178.
    · extracted · source: references/10665-352523.sec-045.137.json
  139. Dian S, Hermawan R, van Laarhoven A, et al. Brain MRI findings in relation to clinical characteristics and outcome of tuberculous meningitis. PLoS One. 15(11): e0241974.
    · extracted · source: references/10665-352523.sec-045.138.json
  140. Garg RK, Malhotra HS, Kumar N, Uniyal R. Vision loss in tuberculous meningitis. J Neurol Sci. 2017;375:27–34.
    · extracted · source: references/10665-352523.sec-045.139.json
  141. Lam KS, Sham MM, Tam SC, et al. Hypopituitarism after tuberculous meningitis in childhood. Ann Intern Med. 1993;118(9):701–706.
    · extracted · source: references/10665-352523.sec-045.140.json
  142. Osman M, Welte A, Dunbar R, et al. Morbidity and mortality up to 5 years post tuberculosis treatment in South Africa: a pilot study. 2019. Int J Infect Dis. 2019;85:57–63.
    · extracted · source: references/10665-352523.sec-045.141.json
  143. Basham CA, Romanowski K, Johnston JC. Life after tuberculosis: planning for health. Lancet Respir Med. 2019;7(12):1004–1006.
    · extracted · source: references/10665-352523.sec-045.142.json
  144. Romanowski K, Baumann B, Basham CA, et al. Long-term all-cause mortality in people treated for tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2019;19(10):1129–1137.
    · extracted · source: references/10665-352523.sec-045.143.json
  145. Marx FM, Cohen T, Menzies NA, et al. Cost-effectiveness of post-treatment follow-up examinations and secondary prevention of tuberculosis in a high-incidence setting: a model-based analysis. Lancet Glob Health. 2020;8(9):e1223–e1233.
    · extracted · source: references/10665-352523.sec-045.144.json
  146. Marx FM, Yaesoubi R, Menzies NA, et al. Tuberculosis control interventions targeted to previously treated people in a high-incidence setting: a modelling study. Lancet Glob Health. 2018;6(4):e426–e435.
    · extracted · source: references/10665-352523.sec-045.145.json
  147. Beydon N, Davis SD, Lombardi E, et al. An official American Thoracic Society/European Respiratory Society statement: pulmonary function testing in preschool children. Am J Respir Crit Care Med. 2007;175(12):1304–1345.
    · extracted · source: references/10665-352523.sec-045.146.json
  148. Guillien A, Soumagne T, Regnard J, Degano B. Les nouvelles équations de référence du Global Lung Function Initiative (GLI) pour les explorations fonctionnelles respiratoires. [The new reference equations of the Global Lung function Initiative (GLI) for pulmonary function tests.] Rev Mal Respir. 2018;35(10):1020–1027.
    · extracted · source: references/10665-352523.sec-045.147.json
  149. Chang AB, Fortescue R, Grimwood K, et al. European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis. Eur Respir J. 2021;58(2):2002990.
    · extracted · source: references/10665-352523.sec-045.148.json
  150. Shah I, Dani S, Shetty NS, et al. Profile of osteoarticular tuberculosis in children. Indian J Tuberc. 2020;67(1):43–45.
    · extracted · source: references/10665-352523.sec-045.149.json
  151. Rajasekaran S. Natural history of Pott’s kyphosis. Eur Spine J. 2013;22(Suppl 4):634–640.
    · extracted · source: references/10665-352523.sec-045.150.json
  152. Mann TN, Schaaf HS, Dunn RN, et al. Child and adult spinal tuberculosis at tertiary hospitals in the Western Cape, South Africa: 4-year burden and trend. Epidemiol Infect. 2018;146(16):2107–2115.
    · extracted · source: references/10665-352523.sec-045.151.json
  153. Dhammi I, Kumar S. Current concepts in diagnosis and management of osteoarticular tuberculosis. Orthop J M P. 2020;26(1):3–13.
    · extracted · source: references/10665-352523.sec-045.152.json
  154. Germain N, Aballéa S, Toumi M. Measuring health-related quality of life in young children: how far have we come? [Published correction appears in J Mark Access Health Policy. 2019;11;7(1):1626572.] J Mark Access Health Policy. 2019;7(1):1618661.
    · extracted · source: references/10665-352523.sec-045.153.json
  155. Verstraete J, Ramma L, Jelsma J. Item generation for a proxy health related quality of life measure in very young children. Health Qual Life Outcomes. 2020;18(1):11.
    · extracted · source: references/10665-352523.sec-045.154.json
  156. Wille N, Badia X, Bonsel G, et al. Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. Qual Life Res. 2010;19(6):875–886.
    · extracted · source: references/10665-352523.sec-045.155.json
  157. Verstraete J, Lloyd A, Scott D, Jelsma J. How does the EQ-5D-Y Proxy version 1 perform in 3, 4 and 5-year-old children? Health Qual Life Outcomes. 2020;18:149.
    · extracted · source: references/10665-352523.sec-045.156.json
  158. Graham SM, Sekadde MP. Case detection and diagnosis of tuberculosis in primary-care settings. Paediatr Int Child Health. 2019;39(2):84–87.
    · extracted · source: references/10665-352523.sec-045.157.json
  159. Dongo JP, Graham SM, Nsonga J, et al. Implementation of an effective decentralised programme for detection, treatment and prevention of tuberculosis in children. Trop Med Infect Dis. 2021;6(3).
    · extracted · source: references/10665-352523.sec-045.158.json
  160. Talukder K, Salim MA, Jerin I, et al. Intervention to increase detection of childhood tuberculosis in Bangladesh. Int J Tuberc Lung Dis. 2012;16(1):70–75.
    · extracted · source: references/10665-352523.sec-045.159.json
  161. Ketema L, Dememew ZG, Assefa D, et al. Evaluating the integration of tuberculosis screening and contact investigation in tuberculosis clinics in Ethiopia: a mixed method study. PLoS One. 2020;15(11):e0241977.
    · extracted · source: references/10665-352523.sec-045.160.json
  162. Maha A, Majumdar SS, Main S, et al. The effects of decentralisation of tuberculosis services in the East New Britain Province, Papua New Guinea. Publ Health Act. 2019;9(Suppl 1):S43-S49.
    · extracted · source: references/10665-352523.sec-045.161.json
  163. Multisectoral accountability framework to accelerate progress to end tuberculosis by 2030. Geneva: World Health Organization; 2019 (https://apps.who.int/iris/handle/10665/331934, accessed 1 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.162.json
  164. WHO Multisectoral Accountability Framework for TB (MAF-TB): baseline assessment checklist for country use in pursuing a national MAF-TB. Geneva: World Health Organization; 2020 (https://www.who.int/docs/default-source/documents/tuberculosis/multisectoral-accountability-framework-tb-tuberculosis-checklist.pdf?sfvrsn=6ba20074_1&download=true, accessed 1 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.163.json
  165. Progress towards the achievement of global tuberculosis targets and implementation of the political declaration of the high-level meeting of the General Assembly on the fight against tuberculosis: report of the Secretary-General. New York: United Nations General Assembly; 2020 (https://apps.who.int/iris/handle/10665/343376, accessed 8 March 2022).
    · extracted · link · source: references/10665-352523.sec-045.164.json
  166. Zawedde-Muyanja S, Nakanwagi A, Dongo JP, et al. Decentralisation of child tuberculosis services increases case finding and uptake of preventive therapy in Uganda. Int J Tuberc Lung Dis. 2018;22(11):1314–1321.
    · extracted · source: references/10665-352523.sec-045.165.json
  167. Khan AJ, Khowaja S, Khan FS, et al. Engaging the private sector to increase tuberculosis case detection: an impact evaluation study. Lancet Infect Dis. 2012;12(8):608–616.
    · extracted · source: references/10665-352523.sec-045.166.json
  168. WHO policy on collaborative TB/HIV activities: guidelines for national programmes and other stakeholders. Geneva: World Health Organization; 2012 (https://apps.who.int/iris/handle/10665/44789, accessed 1 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.167.json
  169. Standards for improving the quality of care for children and young adolescents in health facilities. Geneva: World Health Organization; 2018 (https://apps.who.int/iris/handle/10665/272346, accessed 1 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.168.json
  170. Young M, Wolfheim C, Marsh DR, Hammamy D. World Health Organization/United Nations Children’s Fund joint statement on integrated community case management: an equity-focused strategy to improve access to essential treatment services for children. Am J Trop Med Hyg. 2012;87(5 Suppl):6–10.
    · extracted · source: references/10665-352523.sec-045.169.json
  171. Marais BJ, Obihara CC, Warren RM, et al. The burden of childhood tuberculosis: a public health perspective. Int J Tuberc Lung Dis. 2005;9(12):1305–1313.
    · extracted · source: references/10665-352523.sec-045.170.json
  172. Onazi O, Gidado M, Onazi M, et al. Estimating the cost of TB and its social impact on TB patients and their households. Publ Health Act. 2015;5(2):127–131.
    · extracted · source: references/10665-352523.sec-045.171.json
  173. Goyal-Honavar A, Markose AP, Chhakchhuakk L, et al. Unmasking the human face of TB: the impact of tuberculosis on the families of patients. J Fam Med Prim Care. 2020;9(10):5345–5350.
    · extracted · source: references/10665-352523.sec-045.172.json
  174. Best practices in child and adolescent tuberculosis care. Geneva: World Health Organization; 2018 (https://apps.who.int/iris/handle/10665/274373, accessed 1 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.173.json
  175. Public–private mix for TB prevention and care: a roadmap. Geneva: World Health Organization; 2018 (https://apps.who.int/iris/handle/10665/333885, accessed 1 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.174.json
  176. Stallworthy G, Dias HM, Pai M. Quality of tuberculosis care in the private health sector. J Clin Tuberc Other Mycobact Dis. 2020;20:100171.
    · extracted · source: references/10665-352523.sec-045.175.json
  177. Uplekar M, Juvekar S, Morankar S, et al. Tuberculosis patients and practitioners in private clinics in India. Int J Tuberc Lung Dis. 1998;2(4):324–329.
    · extracted · source: references/10665-352523.sec-045.176.json
  178. Integrating intensive TB case finding and TB preventive treatment services into differentiated ART models: framework for implementation. New York: CQUIN TB/HIV Community of Practice; 2019 (https://cquin.icap.columbia.edu/wp-content/uploads/2020/01/CQUIN-TPT-Toolkit_Jan-2020_Final_Cover.pdf, accessed 1 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.177.json
  179. Maintaining essential health services: operational guidance for the COVID-19 context. Interim guidance: 1 June 2020. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/handle/10665/332240, accessed 3 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.178.json
  180. WHO information note: COVID-19 – considerations for tuberculosis (TB) care. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/341126, accessed 1 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.179.json
  181. Briefing note: testing for both tuberculosis and SARS-CoV-2. Geneva: Global Fund to Fight AIDS, Tuberculosis and Malaria; 2021 (https://www.theglobalfund.org/media/11438/covid19_tb-testing_briefingnote_en.pdf, accessed 3 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.180.json
  182. Cerrone M, Wang X, Neary M, et al. Pharmacokinetics of efavirenz 400 mg once daily coadministered with isoniazid and rifampicin in human immunodeficiency virus-infected individuals. Clin Infect Dis. 2019;68(3):446–452.
    · extracted · source: references/10665-352523.sec-045.181.json
  183. Dooley KE, Sayre P, Borland J, et al. Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr. 2013;62(1):21–27.
    · extracted · source: references/10665-352523.sec-045.182.json
  184. Dooley KE, Kaplan R, Mwelase N, et al. Dolutegravir-based antiretroviral therapy for patients coinfected with tuberculosis and human immunodeficiency virus: a multicenter, noncomparative, open-label, randomized trial. Clin Infect Dis. 2020;70(4):549–556.
    · extracted · source: references/10665-352523.sec-045.183.json
  185. Meintjes G, Rabie H, Wilkinson RJ, Cotton MF. Tuberculosis-associated immune reconstitution inflammatory syndrome and unmasking of tuberculosis by antiretroviral therapy. Clin Chest Med. 2009;30(4):797–810.
    · extracted · source: references/10665-352523.sec-045.184.json
  186. Link-Gelles R, Moultrie H, Sawry S, et al. Tuberculosis immune reconstitution inflammatory syndrome in children initiating antiretroviral therapy for HIV infection: a systematic literature review. Pediatr Infect Dis J. 2014;33(5):499–503.
    · extracted · source: references/10665-352523.sec-045.185.json
  187. Rabie H, Violari A, Duong T, et al. Early antiretroviral treatment reduces risk of bacille Calmette-Guérin immune reconstitution adenitis. Int J Tuberc Lung Dis. 2011;15(9):1194-i.
    · extracted · source: references/10665-352523.sec-045.186.json
  188. Mathad JS, Gupta A. Tuberculosis in pregnant and postpartum women: epidemiology, management, and research gaps. Clin Infect Dis. 2012;55(11):1532–1549.
    · extracted · source: references/10665-352523.sec-045.187.json
  189. Jonsson J, Kuhlmann-Berenzon S, Berggren I, Bruchfeld J. Increased risk of active tuberculosis during pregnancy and postpartum: a register-based cohort study in Sweden. Eur Respir J. 2020;55(3).
    · extracted · source: references/10665-352523.sec-045.188.json
  190. Tuberculosis in women. Geneva: World Health Organization; 2015 (https://www.who.int/tb/challenges/hiv/tb_women_factsheet.pdf, accessed 6 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.189.json
  191. Loto OM, Awowole I. Tuberculosis in pregnancy: a review. J Pregnancy. 2012;2012:379271.
    · extracted · source: references/10665-352523.sec-045.190.json
  192. Gupta A, Nayak U, Ram M, et al. Postpartum tuberculosis incidence and mortality among HIV-infected women and their infants in Pune, India, 2002–2005. Clin Infect Dis. 2007;45(2):241–249.
    · extracted · source: references/10665-352523.sec-045.191.json
  193. Gupta A, Bhosale R, Kinikar A, et al. Maternal tuberculosis: a risk factor for mother-to-child transmission of human immunodeficiency virus. J Infect Dis. 2011;203(3):358–363.
    · extracted · source: references/10665-352523.sec-045.192.json
  194. Gomes VF, Andersen A, Wejse C, et al. Impact of tuberculosis exposure at home on mortality in children under 5 years of age in Guinea-Bissau. Thorax. 2011;66(2):163–167.
    · extracted · source: references/10665-352523.sec-045.193.json
  195. Zenner D, Kruijshaar ME, Andrews N, Abubakar I. Risk of tuberculosis in pregnancy: a national, primary care-based cohort and self-controlled case series study. Am J Respir Crit Care Med. 2012;185(7):779–784.
    · extracted · source: references/10665-352523.sec-045.194.json
  196. Sugarman J, Colvin C, Moran AC, Oxlade O. Tuberculosis in pregnancy: an estimate of the global burden of disease. Lancet Glob Health. 2014;2(12):e710–e716.
    · extracted · source: references/10665-352523.sec-045.195.json
  197. Chabala C, Turkova A, Thomason MJ, et al. Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trial. Trials. 2018;19(1):237.
    · extracted · source: references/10665-352523.sec-045.196.json
  198. Resolution WHA67.19. Strengthening of palliative care as a component of comprehensive care throughout the life course. Geneva: World Health Organization; 2014 (https://apps.who.int/iris/handle/10665/162863, accessed 6 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.197.json
  199. Global atlas of palliative care, 2nd edition. London: Worldwide Palliative Care Alliance; 2020 (http://www.thewhpca.org/resources/global-atlas-on-end-of-life-care, accessed 6 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.198.json
  200. Connor SR. Palliative care for tuberculosis. J Pain Symptom Manage. 2018;55(2S):S178–S180.
    · extracted · source: references/10665-352523.sec-045.199.json
  201. Connor S, Foley K, Harding R, Jaramillo E. Declaration on palliative care and MDR/XDR-TB. Int J Tuberc Lung Dis. 2012;16(6):712–713.
    · extracted · source: references/10665-352523.sec-045.200.json
  202. USAID/TB CARE II Project. Comprehensive guidelines for TB and DR-TB palliative care and support. Bethesda, MD: University Research Co., LLC. (http://www.thewhpca.org/resources/item/south-african-palliative-care-guidelines-for-tb, accessed 8 March 2022.
    · extracted · link · source: references/10665-352523.sec-045.201.json
  203. Clinical practice guidelines for providing palliative care to patients with tuberculosis. Bishkek: Ministry of Health of the Kyrgyz Republic; 2014 (http://www.thewhpca.org/resources?task=callelement&format=raw&item_id=625&element=f85c494b-2b32–4109-b8c1–083cca2b7db6&method=download&args[0]=0f2b19dd0c28b8279b243d317b90f7d4, accessed 6 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.202.json
  204. Integrating palliative care and symptom relief into paediatrics: a WHO guide for health care planners, implementers and managers. Geneva: World Health Organization; 2018 ( https://apps.who.int/iris/handle/10665/274561, accessed 6 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.203.json
  205. Policy brief: palliative care for children with drug-resistant tuberculosis. Bristol: International Children’s Palliative Care Network; 2013 (http://www.riatt-esa.org/s/Policy-Brief-on-Palliative-Care-for-Children-with-Durg-Resistant-TUberculosis-DR-TB.pdf, accessed 6 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.204.json
  206. Palliative care for children with drug-resistant TB: an ICPCN position paper. Bristol: International children’s palliative care network; 2013 (https://www.icpcn.org/wp-content/uploads/2013/07/ICPCN-Position-paper-on-Drug-Resistant-TB.pdf, accessed 6 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.205.json
  207. Assessing the development of palliative care worldwide: a set of actionable indicators. Geneva: World Health Organization; 2021 (https://apps.who.int/iris/handle/10665/345532, accessed 6 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.206.json
  208. Craig F, Henderson EM, Bluebond-Langner M. Management of respiratory symptoms in paediatric palliative care. Curr Opin Support Palliat Care. 2015;9(3):217–226.
    · extracted · source: references/10665-352523.sec-045.207.json
  209. Ringholz F, Devins M, McNally P. Managing end stage lung disease in children. Paediatr Respir Rev. 2014;15(1):75–80.
    · extracted · source: references/10665-352523.sec-045.208.json
  210. Ross DA, Hinton R, Melles-Brewer M, et al. Adolescent well-being: a definition and conceptual framework. J Adolesc Health. 2020;67(4):472–476.
    · extracted · source: references/10665-352523.sec-045.209.json
  211. Kay AW, Thivalapill N, Skinner D, et al. Predictors of suboptimal adherence to isoniazid preventive therapy among adolescents and children living with HIV. PLoS One. 2020;15(12):e0243713.
    · extracted · source: references/10665-352523.sec-045.210.json
  212. Hovell M, Blumberg E, Gil-Trejo L, et al. Predictors of adherence to treatment for latent tuberculosis infection in high-risk Latino adolescents: a behavioral epidemiological analysis. Soc Sci Med. 2003;56(8):1789–1796.
    · extracted · source: references/10665-352523.sec-045.211.json
  213. Kam A, Ford-Jones L, Malloy P, et al. Active tuberculosis among adolescents in Toronto, Canada: clinical features and delays in diagnosis. Pediatr Infect Dis J. 2007;26(4):355–356.
    · extracted · source: references/10665-352523.sec-045.212.json
  214. Nduba V, Hoog AH, Mitchell E, et al. Prevalence of tuberculosis in adolescents, western Kenya: implications for control programs. Int J Infect Dis. 2015;35:11–17.
    · extracted · source: references/10665-352523.sec-045.213.json
  215. Enane LA, Lowenthal ED, Arscott-Mills T, et al. Loss to follow-up among adolescents with tuberculosis in Gaborone, Botswana. Int J Tuberc Lung Dis. 2016;20(10):1320–1325.
    · extracted · source: references/10665-352523.sec-045.214.json
  216. Mulongeni P, Hermans S, Caldwell J, et al. HIV prevalence and determinants of loss-to-follow-up in adolescents and young adults with tuberculosis in Cape Town. PloS One. 2019;14(2):e0210937.
    · extracted · source: references/10665-352523.sec-045.215.json
  217. Enane LA, Eby J, Arscott-Mills T, et al. TB and TB-HIV care for adolescents and young adults. Int J Tuberc Lung Dis. 2020;24(2):240–249.
    · extracted · source: references/10665-352523.sec-045.216.json
  218. Guix-Comellas E-M, Rozas L, Velasco-Arnaiz E, et al. Adherence to antituberculosis drugs in children and adolescents in a low-endemic setting: a retrospective series. Pediat Infect Dis J. 2017;36(6):616–618.
    · extracted · source: references/10665-352523.sec-045.217.json
  219. De Oliveira MCB, Sant’Anna CC, Raggio Luiz R, Kritski AL. Unfavorable outcomes in tuberculosis: multidimensional factors among adolescents in Rio de Janeiro, Brazil. Am J Trop Med Hyg. 2020;103(6):2492–2500.
    · extracted · source: references/10665-352523.sec-045.218.json
  220. Reif LK, Rivera V, Bertrand R, et al. Outcomes across the tuberculosis care continuum among adolescents in Haiti. Publ Health Act. 2018;8(3):103–109.
    · extracted · source: references/10665-352523.sec-045.219.json
  221. Laycock KM, Eby J, Arscott-Mills T, et al. Towards quality adolescent-friendly services in TB care. Int J Tuberc Lung Dis. 2021;25(7):579–583.
    · extracted · source: references/10665-352523.sec-045.220.json
  222. Making health services adolescent friendly: developing national quality standards for adolescent friendly health services. Geneva: World Health Organization; 2012 (https://apps.who.int/iris/handle/10665/75217, accessed 6 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.221.json
  223. Global Accelerated Action for the Health of Adolescents (AA-HA!): guidance to support country implementation – summary. Geneva: World Health Organization; 2017 ( https://apps.who.int/iris/handle/10665/255418, accessed 6 December 2021).
    · extracted · link · source: references/10665-352523.sec-045.222.json
  224. Kazi S, Corcoran H, Abo Y-N, for the ARI Review group. A systematic review of clinical, epidemiological and demographic predictors of tuberculosis in children with pneumonia. J Glob Health (in press). 2022.
    · extracted · source: references/10665-352523.sec-045.223.json
  225. O’Brien KL, Baggett HC, Brooks WA, et al. Causes of severe pneumonia requiring hospital admission in children without HIV infection from Africa and Asia: the PERCH multi-country case-control study. Lancet. 2019;394(10200):757–779.
    · extracted · source: references/10665-352523.sec-045.224.json
  226. Vessière A, Font H, Gabillard D, et al. Impact of systematic early tuberculosis detection using Xpert MTB/RIF Ultra in children with severe pneumonia in high tuberculosis burden countries (TB-Speed pneumonia): a stepped wedge cluster randomized trial. BMC Pediatrics. 2021;21(1):136.
    · extracted · source: references/10665-352523.sec-045.225.json
  227. Marcy O, Font H, Vessière A, for the TB Speed Pneumonia Study Group. Impact of systematic TB detection using Xpert Ultra on nasopharyngeal aspirates and stool samples on mortality in children with severe pneumonia. Presentation. Paris: International Union Against Tuberculosis and Lung Disease; 2021.
    · extracted · source: references/10665-352523.sec-045.226.json
  228. Results of an international cluster randomized trial on systematic tuberculosis detection in children with severe pneumonia. Bordeaux: TB-SPEED Pneumonia; 2021 (https://www.tb-speed.com/wp-content/uploads/2021/10/TB-Speed_Pneumonia_Study_Press_Release_20211021-.pdf, accessed 8 March 2022).
    · extracted · link · source: references/10665-352523.sec-045.227.json
  229. Black RE, Victora CG, Walker SP, et al. Maternal and child undernutrition and overweight in low-income and middle-income countries. Lancet. 2013;382(9890):427–451.
    · extracted · source: references/10665-352523.sec-045.228.json
  230. Patel LN, Detjen AK. Integration of childhood TB into guidelines for the management of acute malnutrition in high burden countries. Public Health Action. 2017;7(2):110–115.
    · extracted · source: references/10665-352523.sec-045.229.json
  231. Jaganath D, Mupere E. Childhood tuberculosis and malnutrition. J Infect Dis. 2012;206(12):1809–1815.
    · extracted · source: references/10665-352523.sec-045.230.json